# Refine Search

**Search Results -**

| Term | Documents |
|---|---|
| (2 NOT 3).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD. | 26 |
| (L2 NOT L3 ).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD. | 26 |

**Database:**
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

**Search:** L4

Refine Search | Recall Text | Clear | Interrupt

## Search History

**DATE: Tuesday, November 23, 2004** Printable Copy Create Case

| Set Name side by side | Query | Hit Count | Set Name result set |
|---|---|---|---|
| *DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND* | | | |
| L4 | L2 not L3 | 26 | L4 |
| L3 | L2 and (primary adj isolate) | 7 | L3 |
| L2 | L1 and (HIV-1) | 33 | L2 |
| L1 | (prime adj boost) adj (vaccine or immunization) | 63 | L1 |

END OF SEARCH HISTORY

**Welcome to DialogClassic Web(tm)**

```
 Dialog level 04.20.00D
Last logoff:  22nov04 13:37:53
Logon file001 23nov04 16:10:11
          *** ANNOUNCEMENT ***
                    ***
--Connect Time joins DialUnits as pricing options on Dialog.
See HELP CONNECT for information.
                    ***
--SourceOne patents are now delivered to your email inbox
as PDF replacing TIFF delivery. See HELP SOURCE1 for more
information.
                    ***
--Important Notice to Freelance Authors--
See HELP FREELANCE for more information
                    ***
NEW FILES RELEASED
***Beilstein Abstracts (File 393)
***Beilstein Facts (File 390)
***Beilstein Reactions (File 391)
***F-D-C Gold/Silver Sheet (File 184)
***BIOSIS Toxicology (File 157)
***IPA Toxicology (File 153)
                    ***
UPDATING RESUMED
                    *** RELOADED
***Toxfile (File 156)

REMOVED
***Textile Technology Digest (File 119)
                    ***

     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>>    of new databases, price changes, etc.      <<<
                    ****
KWIC is set to 50.
HILIGHT set on as ' '
 * * *

File   1:ERIC 1966-2004/Jul 21
       (c) format only 2004 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?
B 155, 5, 73
       23nov04 16:10:31 User259876 Session D693.1
            $0.81    0.230 DialUnits File1
     $0.81  Estimated cost File1
     $0.08  INTERNET
     $0.89  Estimated cost this search
     $0.89  Estimated total session cost   0.230 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R) 1951-2004/Nov W2
        (c) format only 2004 The Dialog Corp.
 *File 155: Medline will stop updating COMPLETED records on November 17,
2004. Please see HELP NEWS 155 for details.
  File   5:Biosis Previews(R) 1969-2004/Nov W2
        (c) 2004 BIOSIS
  File  73:EMBASE 1974-2004/Nov W2
        (c) 2004 Elsevier Science B.V.

      Set  Items  Description
```

```
      ---  -----  -----------
?
S (HIV-1 (W) VACCINE)
          36392  HIV-1
         253917  VACCINE
      S1      0  (HIV-1 (W) VACCINE)
?
S HIV (W) VACCINE
         356490  HIV
         253917  VACCINE
      S2   2077  HIV (W) VACCINE
?
S S2 AND (PRIME-BOOST)
           2077  S2
              0  PRIME-BOOST
      S3      0  S2 AND (PRIME-BOOST)
?
S PRIME-BOOST (W) VACCINE
              0  PRIME-BOOST
         253917  VACCINE
      S4      0  PRIME-BOOST (W) VACCINE
?
S (PRIME (W) BOOST) (W) (VACCINE OR IMMUNIZATION)
          32384  PRIME
          12411  BOOST
         253917  VACCINE
         195281  IMMUNIZATION
      S5    148  (PRIME (W) BOOST) (W) (VACCINE OR IMMUNIZATION)
?
S S2 AND S5
           2077  S2
            148  S5
      S6      6  S2 AND S5
?
RD
...completed examining records
      S7      2  RD (unique items)
?
T S7/3,K/ALL

  7/3,K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

10890917   PMID: 11024131
  A human immunodeficiency virus prime - boost immunization□regimen in□
 humans induces antibodies that show interclade cross-reactivity and
 neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
  Verrier F; Burda S; Belshe R; Duliege A M; Excler J L; Klein M;
Zolla-Pazner S
  Veterans Affairs Medical Center and New York University School of
Medicine, New York, New York 10010, USA.
  Journal of virology (UNITED STATES)  Nov 2000,  74  (21)  p10025-33,
ISSN 0022-538X  Journal Code: 0113724
  Contract/Grant No.: R01-AI 32424; AI; NIAID; R01-AI 36085; AI; NIAID;
R01-HL 59725; HL; NHLBI; +
  Document type: Clinical Trial; Journal Article
  Languages: ENGLISH
  Main Citation Owner: NLM
  Record type: Completed

  A human immunodeficiency virus prime - boost immunization□regimen in□
 humans induces antibodies that show interclade cross-reactivity and
 neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
  A human immunodeficiency virus ( HIV ) vaccine that will be useful in
```

diverse geographic regions will need to induce a broad immune response characterized by cross-clade immunity. To test whether a...

... dualtropic viruses (from clade B) and two R5 viruses (from clades B and C). This is the first demonstration of the induction by a candidate **HIV vaccine** constructed from clade B laboratory strains of HIV of neutralizing activity against R5 and clade C primary isolates. The data suggest that, by virtue of...

**7/3,K/2 (Item 2 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


10527392 PMID: 10630788
**Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after** prime - boost vaccine□regimens with□ **human immunodeficiency virus type 1 canarypox and pseudovirions.**
Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G
Robarts Research Institute, London, Ontario, Canada.
Viral immunology (UNITED STATES) 1999, 12 (4) p281-96, ISSN 0882-8245 Journal Code: 8801552
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after** prime - boost vaccine□regimens with□ **human immunodeficiency virus type 1 canarypox and pseudovirions.**
... in Balb/c mice primed with the recombinant canarypox vector, vCP205, encoding HIV-1 gp120 (MN strain) in addition to Gag/Protease (HIB strain). The **prime - boost immunization** regimens were administered intramuscularly and involved injections of vCP205 followed by boosts with HIV PSV. Previous vaccination strategies solely involving vCP205 had induced good cellular...

... the capability to effectively induce and boost cell-mediated HIV-1-specific responses. In order to observe the immune effects of HIV PSV in a **prime - boost immunization** strategy, both □HIV vaccine□ immunogens required careful titration in vivo. This suggests that careful consideration should be given to the optimization of immunization protocols destined for human use.
?

```
Set     Items   Description
S1          0   (HIV-1 (W) VACCINE)
S2       2077   HIV (W) VACCINE
S3          0   S2 AND (PRIME-BOOST)
S4          0   PRIME-BOOST (W) VACCINE
S5        148   (PRIME (W) BOOST) (W) (VACCINE OR IMMUNIZATION)
S6          6   S2 AND S5
S7          2   RD (unique items)
?
S S5 AND (HIV-1)
            148  S5
          36392  HIV-1
      S8      9  S5 AND (HIV-1)
?
RD
...completed examining records
      S9      9  RD (unique items)
?
S S9 NOT S7
              9  S9
```

```
              2  S7
     S10      7  S9 NOT S7
?
T S10/3,K/ALL
```

**10/3,K/1 (Item 1 from file: 155)**

DIALOG(R)File 155:MEDLINE(R)


16603088 PMID: 15096801

**Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.**

Leung Louisa; Srivastava Indresh K; Kan Elaine; Legg Harold; Sun Yide; Greer Catherine; Montefiori David C; zur Megede Jan; Barnett Susan W
Chiron Corp., Emeryville, California 94608, USA.

AIDS (London, England) (England) Apr 30 2004, 18 (7) p991-1001, ISSN 0269-9370 Journal Code: 8710219
Document type: Evaluation Studies; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... the levels of Env-specific lymphoproliferation. CONCLUSIONS: These results highlight the importance of improving the potency of HIV DNA vaccines by enhanced DNA delivery and **prime - boost vaccine** technologies to generate more robust immune responses in larger animal models. In addition, care must be taken when immunizations with Env and Gag antigens are...

Descriptors: *AIDS Vaccines--immunology--IM; *Gene Products, env --immunology--IM; **HIV-1** --immunology--IM; *Vaccines, DNA--immunology--IM ; Animals; Antibody Affinity; Cell Division--immunology--IM; DNA, Viral --genetics--GE; Gene Products, env--genetics--GE; Gene Products, gag --immunology--IM; HIV Antibodies--biosynthesis--BI; **HIV-1** --genetics--GE; Immunization--methods--MT; Immunization, Secondary--methods--MT; Mutagenesis, Insertional; Papio; T-Lymphocytes, Helper-Inducer--immunology--IM

**10/3,K/2 (Item 2 from file: 155)**

DIALOG(R)File 155:MEDLINE(R)


15078759 PMID: 12928404

**Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.**

Tritel Marc; Stoddard Amy M; Flynn Barbara J; Darrah Patricia A; Wu Chang-you; Wille Ulrike; Shah Javeed A; Huang Yue; Xu Ling; Betts Michael R ; Nabel Gary J; Seder Robert A
Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA.

Journal of immunology (Baltimore, Md. - 1950) (United States) Sep 1 2003, 171 (5) p2538-47, ISSN 0022-1767 Journal Code: 2985117R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... T cell responses, resulting in CD8+ T cell responses far greater in magnitude than Th1 responses. Furthermore, the Th1 and CD8+ T cell responses following **prime - boost immunization** were seen in both lymphoid and peripheral mucosal organs and were sustained over several months. Together, these data suggest a new immunization approach for elicitation...

Descriptors: *AIDS Vaccines--immunology--IM; *Adjuvants, Immunologic

--administration and dosage--AD; *Gene Products, gag--immunology--IM; *HIV Antibodies--biosynthesis--BI; * **HIV-1** --immunology--IM; *Immunization, Secondary--methods--MT; *Oligodeoxyribonucleotides--immunology--IM

**10/3,K/3 (Item 3 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


14233468 PMID: 10029244
**HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.**
Gorse G J; Corey L; Patel G B; Mandava M; Hsieh R H; Matthews T J; Walker M C; McElrath M J; Berman P W; Eibl M M; Belshe R B
St. Louis Department of Veterans Affairs, Medical Center, and Saint Louis University, School of Medicine, Missouri 63106, USA.
AIDS research and human retroviruses (UNITED STATES) Jan 20 1999, 15 (2) p115-32, ISSN 0889-2229 Journal Code: 8709376
Contract/Grant No.: N01-AI-05064; AI; NIAID; N01-AI-15106; AI; NIAID; N01-AI-45211; AI; NIAID; +
Document type: Clinical Trial; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

We evaluated **prime - boost immunization** with two recombinant envelope glycoprotein subunit vaccines (HIV-1MN recombinant gp160 vaccine in alum adjuvant [MN rgp160] and HIV-1MN recombinant gp120 vaccine in alum...
Descriptors: *AIDS Vaccines--immunology--IM; *Acquired Immunodeficiency Syndrome--immunology--IM; *HIV Envelope Protein gp120--immunology--IM; * **HIV-1** --immunology--IM; *Vaccines, Synthetic--immunology--IM

**10/3,K/4 (Item 4 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


13749043 PMID: 9444999
**Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a** prime - boost vaccine **regimen in chimpanzees.**
Zolla-Pazner S; Lubeck M; Xu S; Burda S; Natuk R J; Sinangil F; Steimer K; Gallo R C; Eichberg J W; Matthews T; Robert-Guroff M
Veterans Affairs Medical Center, New York 10010, USA. Zollas01@mcrcr6.med.nyu.edu
Journal of virology (UNITED STATES) Feb 1998, 72 (2) p1052-9, ISSN 0022-538X Journal Code: 0113724
Contract/Grant No.: AI32424; AI; NIAID; AI36085; AI; NIAID
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a** prime - boost vaccine **regimen in chimpanzees.**
Descriptors: *Antibodies, Viral--immunology--IM; *HIV Envelope Protein gp160--immunology--IM; * **HIV-1** --immunology--IM; *T-Lymphocytes--immunology--IM; *Viral Vaccines

**10/3,K/5 (Item 5 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)

13031342 PMID: 8679292
**Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.**
Salmon-Ceron D; Excler J L; Sicard D; Blanche P; Finkielstzjen L; Gluckman J C; Autran B; Matthews T J; Meignier B; Kieny M P; et al
Hopital Cochin, Paris, France.
AIDS research and human retroviruses (UNITED STATES) Dec 1995, 11 (12) p1479-86, ISSN 0889-2229 Journal Code: 8709376
Document type: Clinical Trial; Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... first injection. A weak and short-lived envelope-specific CD(4+)-mediated cytotoxic lymphocyte activity was detected at certain time points in few subjects. This **prime - boost vaccine** approach using rgp160 followed by a V3 peptide was safe in humans, and was able to elicit high levels of neutralizing antibodies and a strong...
...; standards--ST; Adult; CD4-Positive T-Lymphocytes--immunology--IM; CD8-Positive T-Lymphocytes--immunology--IM; Cytotoxicity, Immunologic; HIV Antibodies--biosynthesis--BI; HIV Envelope Protein gp160; **HIV-1** --chemistry--CH; **HIV-1** --genetics--GE; Immunization Schedule; Lymphocyte Activation; Lymphocyte Count--methods--MT; Middle Aged; Neutralization Tests--methods--MT; Random Allocation; Recombinant Proteins--immunology--IM

**10/3,K/6 (Item 6 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


12070678 PMID: 12396607
**Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.**
Verrier Bernard; Le Grand Roger; Ataman-Onal Yasemin; Terrat Celine; Guillon Christophe; Durand Pierre-Yves; Hurtrel Bruno; Aubertin Anne-Marie; Sutter Gerd; Erfle Volker; Girard Marc
UMR 2142 CNRS-BioMerieux, ENSL, 69365 Lyon, France. verrier@cervi-lyon.inserm.fr
DNA and cell biology (United States) Sep 2002, 21 (9) p653-8, ISSN 1044-5498 Journal Code: 9004522
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... second group of monkey was primed with SFV-tat only and boosted with MVA-tat. A third group received a tat and rev DNA/MVA **prime - boost vaccine** regimen. Monitoring of anti-Tat and anti-Rev antibody responses or antigen-specific IFN-gamma production, as measured by enzyme-linked immunospot assays revealed no...
; Animals; Genetic Engineering; HIV Infections--prevention and control --PC; **HIV-1** --immunology--IM; Macaca mulatta; SIV--immunology--IM; Semliki forest virus--immunology--IM; Simian Acquired Immunodeficiency Syndrome --prevention and control--PC; Viral Load

**10/3,K/7 (Item 7 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


11338461 PMID: 11427275
**Immunization of mice with recombinant gp41 in a systemic prime/mucosal**

**boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies.**
Mantis N J; Kozlowski P A; Mielcarz D W; Weissenhorn W; Neutra M R
GI Cell Biology Laboratory, Enders 1220, Children's Hospital, 300 Longwood Avenue, 02115, Boston, MA, USA
Vaccine (England) Jul 16 2001, 19 (28-29) p3990-4001, ISSN 0264-410X Journal Code: 8406899
Contract/Grant No.: AI-34757; AI; NIAID; AI-35365; AI; NIAID; DK-34854; DK; NIDDK; F32 AI10009; AI; NIAID; GM39589; GM; NIGMS; HD-17557; HD; NICHD
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... inducing (SI) or non-syncytium-inducing (NSI) North American HIV-1 field isolates, but not uninfected cells. Thus, this recombinant antigen may be useful in **prime / boost immunization** protocols designed to induce systemic and mucosal antibodies that recognize multiple primary HIV-1 isolates.
Descriptors: *AIDS Vaccines--administration and dosage--AD; *HIV Antibodies--biosynthesis--BI; *HIV Envelope Protein gp41--administration and dosage--AD; * **HIV-1** --immunology--IM; *Immunoglobulin A, Secretory --biosynthesis--BI; *Immunoglobulin G--biosynthesis--BI; AIDS Vaccines --genetics--GE; Animals; Antibody Specificity; HIV Antibodies--blood--BL; HIV Envelope Protein gp41--genetics--GE; **HIV-1** --genetics--GE; Hemagglutinin Glycoproteins, Influenza Virus--administration and dosage--AD ; Hemagglutinin Glycoproteins, Influenza Virus--genetics--GE; Hemagglutinin Glycoproteins, Influenza Virus--immunology--IM; Immunity, Mucosal...
?

```
Set     Items   Description
S1          0   (HIV-1 (W) VACCINE)
S2       2077   HIV (W) VACCINE
S3          0   S2 AND (PRIME-BOOST)
S4          0   PRIME-BOOST (W) VACCINE
S5        148   (PRIME (W) BOOST) (W) (VACCINE OR IMMUNIZATION)
S6          6   S2 AND S5
S7          2   RD (unique items)
S8          9   S5 AND (HIV-1)
S9          9   RD (unique items)
S10         7   S9 NOT S7
?
S S5 AND BX08
             148  S5
              33  BX08
     S11       3  S5 AND BX08
?
RD
...completed examining records
     S12       1  RD (unique items)
?
T S12/3,K/ALL
```

**12/3,K/1 (Item 1 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

12070678 PMID: 12396607
**Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-** BX08 .
Verrier Bernard; Le Grand Roger; Ataman-Onal Yasemin; Terrat Celine; Guillon Christophe; Durand Pierre-Yves; Hurtrel Bruno; Aubertin Anne-Marie; Sutter Gerd; Erfle Volker; Girard Marc
UMR 2142 CNRS-BioMerieux, ENSL, 69365 Lyon, France.

verrier@cervi-lyon.inserm.fr
DNA and cell biology (United States) Sep 2002, 21 (9) p653-8, ISSN 1044-5498 Journal Code: 9004522
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-** BX08 .
... second group of monkey was primed with SFV-tat only and boosted with MVA-tat. A third group received a tat and rev DNA/MVA **prime - boost vaccine** regimen. Monitoring of anti-Tat and anti-Rev antibody responses or antigen-specific IFN-gamma production, as measured by enzyme-linked immunospot assays revealed no...

... be clearly established. The animals were challenged by the rectal route 9 weeks after the last booster immunization, using 10 MID(50) of a SHIV-**BX08** stock. Postchallenge follow-up of the monkeys included testing seroconversion to Gag and Env antigens, measuring virus infectivity in PBMC by cocultivation with noninfected human...
?

| Set | Items | Description |
|---|---|---|
| S1 | 0 | (HIV-1 (W) VACCINE) |
| S2 | 2077 | HIV (W) VACCINE |
| S3 | 0 | S2 AND (PRIME-BOOST) |
| S4 | 0 | PRIME-BOOST (W) VACCINE |
| S5 | 148 | (PRIME (W) BOOST) (W) (VACCINE OR IMMUNIZATION) |
| S6 | 6 | S2 AND S5 |
| S7 | 2 | RD (unique items) |
| S8 | 9 | S5 AND (HIV-1) |
| S9 | 9 | RD (unique items) |
| S10 | 7 | S9 NOT S7 |
| S11 | 3 | S5 AND BX08 |
| S12 | 1 | RD (unique items) |

?
S S5 AND AVIOPOXVIRUS
148 S5
0 AVIOPOXVIRUS
S13 0 S5 AND AVIOPOXVIRUS
?
S S5 AND AVIPOXVIRUS
148 S5
223 AVIPOXVIRUS
S14 3 S5 AND AVIPOXVIRUS
?
RD
...completed examining records
S15 3 RD (unique items)
?
T S15/3,K/ALL

**15/3,K/1 (Item 1 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


11405093 PMID: 11500430
**Multistage multiantigen heterologous** prime boost vaccine **for Plasmodium knowlesi malaria provides partial protection in rhesus macaques.**
Rogers W O; Baird J K; Kumar A; Tine J A; Weiss W; Aguiar J C; Gowda K; Gwadz R; Kumar S; Gold M; Hoffman S L
Malaria Program, Naval Medical Research Center, Silver Spring, Maryland 20910, Bethesda, Maryland 20889, USA. Rogersb@nmrc.navy.mil
Infection and immunity (United States) Sep 2001, 69 (9) p5565-72,

ISSN 0019-9567 Journal Code: 0246127
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**Multistage multiantigen heterologous** prime boost vaccine **for Plasmodium knowlesi malaria provides partial protection in rhesus macaques.**
Descriptors: *Antigens, Protozoan--immunology--IM; * **Avipoxvirus** --genetics--GE; *Malaria--prevention and control--PC; *Malaria Vaccines; *Plasmodium knowlesi--immunology--IM; *Vaccines, DNA; Animals; Antibodies, Protozoan--blood--BL; Antigens, Protozoan--genetics--GE; Antigens, Protozoan--metabolism--ME; **Avipoxvirus** --immunology--IM; Immunization, Secondary--methods--MT; Interferon Type II--biosynthesis--BI; Macaca mulatta; Malaria Vaccines--administration and dosage--AD; Malaria Vaccines --immunology--IM; Mice; Parasitemia...

**15/3,K/2 (Item 2 from file: 155)**


11220434 PMID: 11257394
**Therapeutic vaccines against melanoma and colorectal cancer.**
Tartaglia J; Bonnet M C; Berinstein N; Barber B; Klein M; Moingeon P
Aventis Pasteur, Research and Development, Willowdale, Canada.
Vaccine (England) Mar 21 2001, 19 (17-19) p2571-5, ISSN 0264-410X Journal Code: 8406899
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... of intratumoral administration of recombinant canarypox viruses carrying cytokine genes. Our current focus is on the induction of tumor-specific T-cell responses using a **prime / boost immunization** schedule with a unique vector system derived from the canary pox virus called ALVAC, in which we incorporate genes encoding Tumor Associated Antigens (TAAs) of...
; Antigens, Neoplasm--genetics--GE; **Avipoxvirus** --genetics--GE; Cancer Vaccines--genetics--GE; Cancer Vaccines--immunology--IM; Clinical Trials; Colorectal Neoplasms--immunology--IM; Cytokines--genetics--GE; Genetic Vectors; Melanoma--immunology--IM; Safety...

**15/3,K/3 (Item 3 from file: 155)**


10527392 PMID: 10630788
**Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after** prime - boost vaccine□regimens with□ **human immunodeficiency virus type 1 canarypox and pseudovirions.**
Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G
Robarts Research Institute, London, Ontario, Canada.
Viral immunology (UNITED STATES) 1999, 12 (4) p281-96, ISSN 0882-8245 Journal Code: 8801552
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after** prime - boost vaccine□regimens with□ **human immunodeficiency virus type 1 canarypox and pseudovirions.**

... in Balb/c mice primed with the recombinant canarypox vector, vCP205, encoding HIV-1 gp120 (MN strain) in addition to Gag/Protease (HIB strain). The **prime - boost immunization** regimens were administered intramuscularly and involved injections of vCP205 followed by boosts with HIV PSV. Previous vaccination strategies solely involving vCP205 had induced good cellular...

... the capability to effectively induce and boost cell-mediated HIV-1-specific responses. In order to observe the immune effects of HIV PSV in a **prime - boost immunization** strategy, both HIV vaccine immunogens required careful titration in vivo. This suggests that careful consideration should be given to the optimization of immunization protocols destined...
Descriptors: *AIDS Vaccines--immunology--IM; * **Avipoxvirus** --immunology --IM; *HIV Envelope Protein gp120--immunology--IM; *HIV-1--immunology--IM; *T-Lymphocytes, Cytotoxic--immunology--IM; *Virion--immunology--IM; Animals ; **Avipoxvirus** --genetics--GE; Cytotoxicity, Immunologic; Gene Products, gag--genetics--GE; Gene Products, gag--immunology--IM; HIV Envelope Protein gp120--genetics--GE; HIV Infections--prevention and control...
?

```
Set     Items   Description
S1          0   (HIV-1 (W) VACCINE)
S2       2077   HIV (W) VACCINE
S3          0   S2 AND (PRIME-BOOST)
S4          0   PRIME-BOOST (W) VACCINE
S5        148   (PRIME (W) BOOST) (W) (VACCINE OR IMMUNIZATION)
S6          6   S2 AND S5
S7          2   RD (unique items)
S8          9   S5 AND (HIV-1)
S9          9   RD (unique items)
S10         7   S9 NOT S7
S11         3   S5 AND BX08
S12         1   RD (unique items)
S13         0   S5 AND AVIOPOXVIRUS
S14         3   S5 AND AVIPOXVIRUS
S15         3   RD (unique items)
?
S S5 AND (ATTENUATED (W) VIRAL (W) VECTOR)
             148  S5
          184443  ATTENUATED
          688552  VIRAL
          277793  VECTOR
               2  ATTENUATED(W)VIRAL(W)VECTOR
     S16       0  S5 AND (ATTENUATED (W) VIRAL (W) VECTOR)
?
S (ATTENUATED (W) VIRAL (W) VECTOR)
          184443  ATTENUATED
          688552  VIRAL
          277793  VECTOR
     S17       2  (ATTENUATED (W) VIRAL (W) VECTOR)
?
RD
...completed examining records
     S18       2  RD (unique items)
?
T S18/3,K/ALL

  18/3,K/1      (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0014966606   BIOSIS NO.: 200400337395
 Modified immunogenic pneumolysin compositions as vaccines
AUTHOR: Minetti Conceicao (Reprint); Michon Francis; Pullen Jeffrey K;
```

Polvino-Bodnar Mary Ellen; Liang Shu-Mei; Tai Joseph Y
AUTHOR ADDRESS: Silver Spring, MD, USA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1284 (3): July 20, 2004 2004
MEDIUM: e-file
PATENT NUMBER: US 6764686 PATENT DATE GRANTED: July 20, 2004 20040720
PATENT CLASSIFICATION: 424-2361 PATENT ASSIGNEE: Baxter International Inc.
PATENT COUNTRY: USA
ISSN: 0098-1133 _(ISSN print)
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: immunity against Streptococcus pneumoniae. The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an **attenuated viral vector** . In addition, the invention also provides a method of using the non-toxic, modified pneumolysin toxoid in order to stimulate antibodies against Streptococcus pneumoniae in...

**18/3,K/2 (Item 2 from file: 5)**
DIALOG(R)File 5:Biosis Previews(R)


0012324200 BIOSIS NO.: 200000042513
**Use of a two-phase partitioning system to purify an immunologically attenuated viral vector**
AUTHOR: Mizouni S K (Reprint); Bradley A J (Reprint); Scott M D (Reprint)
AUTHOR ADDRESS: Albany Medical College, Albany, NY, USA**USA
JOURNAL: Blood 94 (10 SUPPL. 1 PART 2): p415b Nov. 15, 1999 1999
MEDIUM: print
CONFERENCE/MEETING: Forty-first Annual Meeting of the American Society of Hematology New Orleans, Louisiana, USA December 3-7, 1999; 19991203
SPONSOR: The American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

**Use of a two-phase partitioning system to purify an immunologically attenuated viral vector**
?

| Set | Items | Description |
|---|---|---|
| S1 | 0 | (HIV-1 (W) VACCINE) |
| S2 | 2077 | HIV (W) VACCINE |
| S3 | 0 | S2 AND (PRIME-BOOST) |
| S4 | 0 | PRIME-BOOST (W) VACCINE |
| S5 | 148 | (PRIME (W) BOOST) (W) (VACCINE OR IMMUNIZATION) |
| S6 | 6 | S2 AND S5 |
| S7 | 2 | RD (unique items) |
| S8 | 9 | S5 AND (HIV-1) |
| S9 | 9 | RD (unique items) |
| S10 | 7 | S9 NOT S7 |
| S11 | 3 | S5 AND BX08 |
| S12 | 1 | RD (unique items) |
| S13 | 0 | S5 AND AVIOPOXVIRUS |
| S14 | 3 | S5 AND AVIPOXVIRUS |
| S15 | 3 | RD (unique items) |
| S16 | 0 | S5 AND (ATTENUATED (W) VIRAL (W) VECTOR) |
| S17 | 2 | (ATTENUATED (W) VIRAL (W) VECTOR) |
| S18 | 2 | RD (unique items) |

?
S S2 AND REVIEW

```
            2077  S2
         1745373  REVIEW
     S19     227  S2 AND REVIEW
?
S S19 NOT PY<2000
Processing
             227  S19
        32704959  PY<2000
     S20     140  S19 NOT PY<2000
?
RD
...examined 50 records  (50)
...examined 50 records  (100)
...completed examining records
     S21      97  RD (unique items)
?
T S21/3,K/1-10
```

**21/3,K/1 (Item 1 from file: 155)**

DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

17040689 PMID: 15285711

**Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens.**

Paterson Yvonne; Johnson Ross S

University of Pennsylvania, 323 Johnson Pavilion, 36th St. and Hamilton Walk, Philadelphia, PA 19104-6076, USA. yvonne@mail.med.upenn.edu

Expert review of vaccines (England) Aug 2004, 3 (4 Suppl) pS119-34, ISSN 1476-0584 Journal Code: 101155475

Contract/Grant No.: AI 36657; AI; NIAID

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Process

... for the presentation of passenger antigens to the major histocompatability complex class II and class I pathways of antigen processing and presentation. This article shall **review** the progress made in developing this unusual bacterium as a vaccine vector. In mouse models, recombinant Listeria carrying a number of different antigens have been...

... oral and parenteral immunization, and in the rhesus macaque after oral immunization indicate that strong cell-mediated immunity can be induced against these antigens. This **review** also discusses safety issues associated with live bacterial vaccine vectors and problems to be overcome in developing Listeria as a **HIV vaccine** for human use.

**21/3,K/2 (Item 2 from file: 155)**

DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

17040682 PMID: 15285704

**Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.**

Srivastava Indresh K; Ulmer Jeffrey B; Barnett Susan W

Chiron Vaccines, 4560 Horton Street, Emeryville, CA 94608, USA. indresh srivastava@chiron.com

Expert review of vaccines (England) Aug 2004, 3 (4 Suppl) pS33-52, ISSN 1476-0584 Journal Code: 101155475

Contract/Grant No.: 1-AI-05396; AI; NIAID; 5 PO1 AI48225-03; AI; NIAID; AI-95367; AI; NIAID

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM
Record type: In Process

... a major health problem throughout the world with a high degree of mortality and morbidity. Therefore, there is an urgent need for an effective anti- **HIV vaccine** . Although the correlates of protective immunity against infection by HIV remain unidentified, recent studies have demonstrated that both humoral and cellular responses are required for... ... of viral replication in the infected host. Finally, cytotoxic T-lymphocytes may facilitate the clearance of virally infected cells. One of the biggest challenges in **HIV vaccine** development is to design a HIV envelope immunogen that can induce protective neutralizing antibodies effective against the diverse HIV-1 strains that characterize the global pandemic. The focus of this article is to **review** the importance of antibodies and the strategies that are currently being used for inducing such antibodies.

**21/3,K/3 (Item 3 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


16487841 PMID: 15078177
**Humoral immunity in HIV-1 exposure: cause or effect of HIV resistance?**
Lopalco Lucia
Clinics for Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy. lucia.lopalco@hsr.it
Curr HIV Res (Netherlands) Apr 2004, 2 (2) p127-39, ISSN 1570-162X Journal Code: 101156990
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... all over the world. Despite the huge effort in basic and applied research, aimed to control virus spread and to design effective therapeutic strategies, an **HIV vaccine** is not available yet and current therapeutics approaches cannot prevent the infection. To date, both host genetic repertoire, innate and acquired immune responses, viral mutation...

... responses, e.g. the generation of neutralising antibodies directed against common targets, which can play a protective role in virus entry and/or spread. This **review** focuses on naturally occurring humoral responses to HIV exposure/infection. Moreover, whether such antibodies are induced in response to a peculiar scenario of HIV infection...

**21/3,K/4 (Item 4 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


16458936 PMID: 15233732
**DNA vaccines against human immunodeficiency virus type 1.**
Estcourt Marie J; McMichael Andrew J; Hanke Tomas
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK.
Immunological reviews (Denmark) Jun 2004, 199 p144-55, ISSN 0105-2896 Journal Code: 7702118
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: In Process

Development of a vaccine against human immunodeficiency virus type 1 (HIV-1) is the main hope for controlling the acquired immunodeficiency

syndrome pandemic. An ideal **HIV vaccine** should induce neutralizing antibodies, CD4+ helper T cells, and CD8+ cytotoxic T cells. While the induction of broadly neutralizing antibodies remains a highly challenging goal...

... inducing potent cell-mediated responses in animal models, which are now starting to be tested in humans. Naked DNA immunization is one of them. This **review** focuses on the stimulation of HIV-specific T cells and discusses in the context of the current 'state-of-art' of DNA vaccines, the areas where this technology might assist either alone or as a part of more complex vaccine formulations in the **HIV vaccine** development.

**21/3,K/5 (Item 5 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


16103737 PMID: 12871196
**Bioorganic approaches towards** HIV vaccine□ design.□
Wang Lai-Xi
Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, 725 W. Lombard Street, Baltimore, MD 21201, USA. wangx@umbi.umd.edu
Current pharmaceutical design (Netherlands) 2003, 9 (22) p1771-87, ISSN 1381-6128 Journal Code: 9602487
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**Bioorganic approaches towards** HIV vaccine□ design.□
... gp120 as a preventive vaccine was not fulfilled. Broadly neutralizing antibodies and HIV-specific cytotoxic T lymphocytes (CTL) are two immune effectors that an effective **HIV vaccine** may have to elicit. Experiments in animal models have proved that sufficient levels of neutralizing antibodies can clean up the virus and protect the animals from viral challenge. Therefore, the induction of a broadly neutralizing antibody response remains a principal goal in **HIV vaccine** development. To achieve persistent infection, HIV has evolved elegant strategies to evade host immune surveillance. These include envelope oligomerization, rapid mutation, heavy glycosylation, and conformational...

... to the immune system. This in turn has greatly facilitated a rational design of immunogens capable of eliciting broadly neutralizing antibodies against HIV. The present **review** provides an overview of the major scientific obstacles we are facing in the development of an effective **HIV vaccine** , and discusses recent progresses in the field with a focus on current approaches toward a neutralizing antibody-based **HIV vaccine** . The bioorganic aspects of the approaches are emphasized.

**21/3,K/6 (Item 6 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


15633700 PMID: 14765474
**HIV vaccines: current challenges and future directions.**
Avrett Sam; Collins Chris
Canadian HIV/AIDS policy & law review / Canadian HIV/AIDS Legal Network ( Canada) Jul 2002, 7 (1) p1, 20-5, ISSN 1496-399X Journal Code: 101125215
Document type: Newspaper Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Volume seven of the **Review** will mark the tenth anniversary of the Canadian HIV/AIDS Legal Network with a series of articles that describe past developments and future directions in...

... to develop and provide access to HIV vaccines. It further explains what is required for governments to fulfill their obligations: additional commitment and resources for **HIV vaccine** development in the context of increased global research and development regarding diseases of the poor; increased support and advocacy for partnerships to develop HIV vaccines; enhanced regulatory capacity in every country to **review** , approve, and monitor HIV vaccines; and assurance of global supply of, procurement of, delivery of, and access to vaccines in the context of efforts to...

**21/3,K/7 (Item 7 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


15482098 PMID: 14598567
**Adenoviruses as vectors for HIV vaccines.**
Gomez-Roman Victor Raul; Robert-Guroff Marjorie
Basic Research Laboratory, National Cancer Institute, National Institutes of Health, 41 Library Drive, Building 41, Room D804, Bethesda, MD 20892-5055, USA.
AIDS reviews (Spain) Jul-Sep 2003, 5 (3) p178-85, ISSN 1139-6121 Journal Code: 101134876
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

The tropism of adenoviruses (Ad) for mucosal epithelium makes them ideal vectors for the development of recombinant Ad-HIV vaccines. Currently, several Ad- **HIV vaccine** candidates are being tested in clinical and preclinical trials. Here, we **review** the progress on the safety, immunogenicity and efficacy of replication-competent and replication-defective Ad-HIV and Ad-SIV vaccines in animal models, including non...

**21/3,K/8 (Item 8 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


15332580 PMID: 12016434
**HIV-1 polymorphism: a challenge for vaccine development - a** review .
Morgado M G; Guimaraes M L; Galvao-Castro B
Laboratorio de AIDS e Imunologia Molecular, Departamento de Imunologia, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, RJ, 21045-900, Brasil. mmorgado@ioc.fiocruz.br
Memorias do Instituto Oswaldo Cruz (Brazil) Mar 2002, 97 (2) p143-50 , ISSN 0074-0276 Journal Code: 7502619
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**HIV-1 polymorphism: a challenge for vaccine development - a** review .
...genetic variability and the limited understanding of the immunological correlates of protection have made this an enormous scientific challenge not overcome so far. In this **review** we presented an updating of HIV-1 subtypes and recombinant viruses circulating in South American countries, focusing mainly on Brazil, as one of the challenges for **HIV vaccine** development. Moreover, we discussed the importance of stimulating

. developing countries to participate in the process of vaccine evaluation, not only testing vaccines according to already...

**21/3,K/9 (Item 9 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


12494788 PMID: 12957818
**Lentivirus infections and mechanisms of disease resistance in chimpanzees.**
Rutjens Erik; Balla-Jhagjhoorsingh Sunita; Verschoor Ernst; Bogers Willy; Koopman Gerrit; Heeney Jonathan
Department of Virology, the Biomedical Primate Research Centre, Lange Kleiweg 139, 2288 GJ, Rijswijk, The Netherlands.
Frontiers in bioscience - a journal and virtual library (United States) Sep 1 2003, 8 pd1134-45, ISSN 1093-4715 Journal Code: 9709506
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... late 1980s, as the AIDS epidemic spread globally in humans, the chimpanzee was eagerly looked to for answers concerning effective AIDS therapies and a possible **HIV vaccine** . Although from the complicated inter-relationship of the AIDS virus with the human immune system, neither an effective vaccine nor a therapy has emerged, one...

... the spotlight has recently been turned once again on to the chimpanzee, in the intense search for the origin of the AIDS epidemic. Here we **review** the history of HIV-1 infection in this species as well as the observations that have led to some of the current leading hypotheses regarding...

**21/3,K/10 (Item 10 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


12456227 PMID: 12876900
**Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.**
Blower S; Schwartz E J; Mills J
AIDS Institute & Department of Biomathematics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1766, USA. sblower@mednet.ucla.edu
AIDS reviews (Spain) Apr-Jun 2003, 5 (2) p113-25, ISSN 1139-6121 Journal Code: 101134876
Contract/Grant No.: 5 T32 AI07370; AI; NIAID; RO1 AI41935; AI; NIAID
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Mathematical models can be used as health policy tools and predictive tools. Here we **review** how mathematical models have been used both to predict the consequences of specific epidemic control strategies and to design epidemic control strategies. We **review** how models have been used to evaluate the potential impact on HIV epidemics of (i) combination antiretroviral therapies (ART) and (ii) imperfect vaccines. In particular ...

... discuss, in detail, how mathematical models have been used to evaluate the potential impact of prophylactic, live-attenuated and therapeutic HIV vaccines. We show how **HIV vaccine** models can be used to evaluate the epidemic-level impact of vaccine efficacy, waning in vaccine-induced

immunity, vaccination coverage level, and changes (increases or...
?

| Set | Items | Description |
|---|---|---|
| S1 | 0 | (HIV-1 (W) VACCINE) |
| S2 | 2077 | HIV (W) VACCINE |
| S3 | 0 | S2 AND (PRIME-BOOST) |
| S4 | 0 | PRIME-BOOST (W) VACCINE |
| S5 | 148 | (PRIME (W) BOOST) (W) (VACCINE OR IMMUNIZATION) |
| S6 | 6 | S2 AND S5 |
| S7 | 2 | RD (unique items) |
| S8 | 9 | S5 AND (HIV-1) |
| S9 | 9 | RD (unique items) |
| S10 | 7 | S9 NOT S7 |
| S11 | 3 | S5 AND BX08 |
| S12 | 1 | RD (unique items) |
| S13 | 0 | S5 AND AVIOPOXVIRUS |
| S14 | 3 | S5 AND AVIPOXVIRUS |
| S15 | 3 | RD (unique items) |
| S16 | 0 | S5 AND (ATTENUATED (W) VIRAL (W) VECTOR) |
| S17 | 2 | (ATTENUATED (W) VIRAL (W) VECTOR) |
| S18 | 2 | RD (unique items) |
| S19 | 227 | S2 AND REVIEW |
| S20 | 140 | S19 NOT PY<2000 |
| S21 | 97 | RD (unique items) |

?
T S21/3,K/11-20

**21/3,K/11 (Item 11 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

12385857 PMID: 12769793
**Immunological approaches for HIV therapy.**
Lori F; Kelly L M; Lisziewicz J
Research Institute for Genetic and Human Therapy, at IRCCS Policlinico S. Matteo, Pavia, Italy. rightpv@tin.it
Current drug targets. Infectious disorders (Netherlands) Jun 2003, 3 (2) p171-8, ISSN 1568-0053 Journal Code: 101128002
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... of a successful vaccine are the selection of administration route, heterologous or homologous prime/boost schedules, and the feasibility of the eventual clinical application. This **review** will summarize recently developed preventive and therapeutic vaccines, and carefully evaluate the advantages and potential risks for Human Immunodeficiency Virus (HIV) infected patients. Finally, the concept of "autovaccination" will be defined as it represents the basis for the development of our innovative therapeutic antigen presenting cell targeted **HIV vaccine** . DermaVir is the first topical vaccine, in combination with antiretroviral therapy, to demonstrate immunological and clinical benefits in a relevant animal model (chronically infected rhesus...

**21/3,K/12 (Item 12 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

12333531 PMID: 12699365
**HIV vaccines in infants and children: past trials, present plans and future perspectives.**
Safrit Jeffrey T

Elizabeth Glaser Pediatric AIDS Foundation, Department of Pediatrics, David Geffin School of Medicine, University of California, Los Angeles, USA. jeff@pedaids.org
Current molecular medicine (Netherlands) May 2003, 3 (3) p303-12, ISSN 1566-5240 Journal Code: 101093076
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

This **review** will address the recent history in **HIV** **vaccine** trials in the pediatric population while giving due respect to the pediatric vaccine successes achieved over the past decades. Success and failure seen when utilizing the neonatal macaque model of SIV infection and the ramifications of these studies will be discussed. The short list of pediatric **HIV** **vaccine** trials currently in progress and those in early planning stages will be reviewed. Finally, future perspectives on the impact of a vaccine that could be...

**21/3,K/13 (Item 13 from file: 155)**


12333526 PMID: 12699360
**Dendritic cells as a conduit to improve HIV vaccines.**
Pope Melissa
Center for Biomedical Research, Population Council, 1230 York Avenue, New York, NY 10021, USA. mpope@popcbr.rockefeller.edu
Current molecular medicine (Netherlands) May 2003, 3 (3) p229-42, ISSN 1566-5240 Journal Code: 101093076
Contract/Grant No.: AI40877; AI; NIAID; AI52048; AI; NIAID; AI52060; AI; NIAID; HD41752; HD; NICHD
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Many potential **HIV** **vaccine** strategies are being explored in both animal model and human settings. The success of any vaccine relies on relevant antigenic determinants being presented to the...

...vaccine antigen would be greatly enhanced if targeted to the appropriate DCs to ensure optimal presentation to and subsequently activation of the immune system. This **review** will discuss (i) the current status of DC biology, covering distinct DC subsets and stages of activation and how these influence the types of immune responses that are induced, (ii) how DCs can be exploited to improve the efficacy of **HIV** **vaccine** strategies currently under investigation, (iii) what has been learned from in vivo model systems using DCs, and (iv) future considerations to advance HIV vaccinology.

**21/3,K/14 (Item 14 from file: 155)**


12333525 PMID: 12699359
**The role of mucosal immunity in prevention of HIV transmission.**
Kozlowski Pamela A; Neutra Marian R
GI Cell Biology Research Laboratory, Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. pamela.kozlowski@TCH.Harvard.edu
Current molecular medicine (Netherlands) May 2003, 3 (3) p217-28, ISSN 1566-5240 Journal Code: 101093076

Contract/Grant No.: AI34757; AI; NIAID; AI35365; AI; NIAID; AI48133; AI; NIAID
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... protection against mucosal transmission of HIV or SIV, whereas cytotoxic T cells are required for clearance of mucosal infection and prevention of systemic spread. This **review** summarizes the roles of IgA and IgG antibodies in preventing mucosal infection by other viral and bacterial pathogens, and then discusses the various mechanisms by...
... locally infected cells through antibody-dependent cell-mediated cytotoxic reactions. The regional nature of mucosal immune responses is reviewed in light of its relevance to **HIV vaccine** development. We conclude that mucosal immunization should be considered a component of vaccine strategies against HIV.

**21/3,K/15 (Item 15 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


12180686 PMID: 12516046
**A review of vaccines for HIV prevention.**
Mwau Matilu; McMichael Andrew J
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
journal of gene medicine (England) Jan 2003, 5 (1) p3-10, ISSN 1099-498X Journal Code: 9815764
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**A review of vaccines for HIV prevention.**
... attitude and culture that accelerate the spread of HIV/AIDS have had only modest success. There is urgent need for a prophylactic and/or therapeutic **HIV vaccine** . This is a **review** of the obstacles and current trends in **HIV vaccine** development. Copyright 2002 John Wiley & Sons, Ltd.

**21/3,K/16 (Item 16 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


12162574 PMID: 11790602
**The past, present and future of** HIV - vaccine□development: a critical□ **view.**
Bojak Alexandra; Deml Ludwig; Wagner Ralf
Institute of Medical Microbiology and Hygiene, Franz-Josef-Strauss Allee 11, 93053 Regensburg, Germany.
Drug discovery today (England) Jan 1 2002, 7 (1) p36-46, ISSN 1359-6446 Journal Code: 9604391
Document type: Historical Article; Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**The past, present and future of** HIV - vaccine□development: a critical□ **view.**
... to combat AIDS, the global number of HIV-1 infections is still increasing. There is major consent among scientists worldwide, that the

development of successful **HIV vaccine** strategies requires a profound understanding of the epidemiological principles of a viral pandemic, as well as deep insights into the molecular and immunological mechanisms of HIV pathogenesis. This **review** provides an overview of past and present developments, as well as future aspects of HIV vaccines, and also provides a summary of current clinical trials...

**21/3,K/17 (Item 17 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


12105315 PMID: 12433353
**[Present situation regarding development of an** HIV vaccine□]□
Situacion actual en el desarrollo de una vacuna frente al virus de la inmunodeficiencia humana.
Alcami Jose
Unidad de Inmunopatologia del SIDA. Centro Nacional de Microbiologia. Instituto de Salud Carlos III. Madrid. Espana. ppalcami@isciii.es
Enfermedades infecciosas y microbiologia clinica (Spain) Dec 2002, 20 (10) p511-22, ISSN 0213-005X Journal Code: 9104081
Document type: Journal Article; Review; Review, Tutorial ; English Abstract
Languages: SPANISH
Main Citation Owner: NLM
Record type: Completed

**[Present situation regarding development of an** HIV vaccine□]□
The AIDS epidemic continues to advance, and the development of a preventive **HIV vaccine** has become a major objective for scientific research. An effective vaccine against this virus is not available and complete protection still has not been achieved in animal models. In this **review** the major challenges related to the development of a vaccine against HIV are analyzed, particularly the mechanisms involved in viral escape from the immune response...

**21/3,K/18 (Item 18 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


11907048 PMID: 12103304
**HIV/AIDS treatment and HIV vaccines for Africa.**
Weidle Paul J; Mastro Timothy D; Grant Alison D; Nkengasong John; Macharia Doris
Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. pweidle@cdc.gov
Lancet (England) Jun 29 2002, 359 (9325) p2261-7, ISSN 0140-6736 Journal Code: 2985213R
Comment in Lancet. 2002 Nov 2;360(9343) 1424; Comment in PMID 12424013
Document type: Journal Article; Review; Review, Academic
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... In resource-poor settings, antiretroviral drugs should be given with use of standardised treatment regimens and streamlined algorithms for monitoring use. A safe and effective **HIV vaccine** will supplement prevention efforts to protect uninfected people against infection, or might possibly be able to modify the course of HIV infection. Advances have been ...
... immune response and immunisation to HIV, and new ideas for candidate vaccines have been developed, including several based on HIV-1 strains prevalent in Africa. **HIV vaccine** efficacy trials are needed in Africa

. to determine whether these advances can be translated into clinical and public health benefits. In this **review** , we discuss the prospects for use of treatment and vaccines in resource-poor settings.

**21/3,K/19 (Item 19 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


11694444 PMID: 11868934
**Vaccine development against HIV-1: current perspectives and future directions.**
Edgeworth Rebecca L; San Juan Homero; Rosenzweig Jason A; Nguyen Nang L; Boyer Jean D; Ugen Kenneth E
Department of Medical Microbiology and Immunology, University of South Florida, College of Medicine, Tampa 33612, USA.
Immunologic research (United States) 2002, 25 (1) p53-74, ISSN 0257-277X Journal Code: 8611087
Contract/Grant No.: P01 AI43069; AI; NIAID
Document type: Journal Article; Review; Review, Academic
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... virus (HIV) is of great urgency, because it is accepted that vaccination is the only means capable of controlling the AIDS pandemic. The foundation of **HIV vaccine** development is the analysis of immune responses during natural infection and the utilization of this knowledge for the development of protective immunization strategies. Initial vaccine ...
... has focused on the development of appropriate chemical and genetic adjuvants as well as methods of vaccine delivery to improve the host immune response. This **review** summarizes the vaccine strategies that have been tested in both animal models and human clinical trials.

**21/3,K/20 (Item 20 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


11689382 PMID: 11863014 Record Identifier: 101297; VF 9.5.6
**Ethical issues in** HIV vaccine trials in South Africa.
Slack C; Lindegger G; Vardas E; Richter L; Strode A; Wassenaar D
School of Psychology, University of Natal, Private Bag X01, Scottsville, 3209 South Africa.
South African journal of science (South Africa) Jun 2000, 96 p291-5, ISSN 0038-2353 Journal Code: 0066654
KIE Bib: AIDS/human experimentation; human experimentation/foreign countries; immunization
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: KIE
Other Citation Owner: KIE; NRCBL
Record type: Completed

**Ethical issues in** HIV vaccine trials in South Africa.
In this **review** we describe the ethical issues central to local and international debates about **HIV vaccine** trials. These issues include the physiological and psycho-social risks of trial participation, the preventative interventions to be provided to participants, access to treatment for...
?

| Set | Items | Description |
|---|---|---|
| S1 | 0 | (HIV-1 (W) VACCINE) |

```
S2        2077   HIV (W) VACCINE
S3           0   S2 AND (PRIME-BOOST)
S4           0   PRIME-BOOST (W) VACCINE
S5         148   (PRIME (W) BOOST) (W) (VACCINE OR IMMUNIZATION)
S6           6   S2 AND S5
S7           2   RD (unique items)
S8           9   S5 AND (HIV-1)
S9           9   RD (unique items)
S10          7   S9 NOT S7
S11          3   S5 AND BX08
S12          1   RD (unique items)
S13          0   S5 AND AVIOPOXVIRUS
S14          3   S5 AND AVIPOXVIRUS
S15          3   RD (unique items)
S16          0   S5 AND (ATTENUATED (W) VIRAL (W) VECTOR)
S17          2   (ATTENUATED (W) VIRAL (W) VECTOR)
S18          2   RD (unique items)
S19        227   S2 AND REVIEW
S20        140   S19 NOT PY<2000
S21         97   RD (unique items)
?
T S21/3,K/21-30
```

**21/3,K/21 (Item 21 from file: 155)**

DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

11610104 PMID: 11782252
**Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection.**
O'Connor D; Friedrich T; Hughes A; Allen T M; Watkins D
Immunological reviews (Denmark) Oct 2001, 183 p115-26, ISSN 0105-2896 Journal Code: 7702118
Document type: Journal Article; Review; Review, Academic
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Infection of rhesus macaques with simian immunodeficiency virus (SIV) is an excellent model system for studying viral adaptation to immune responses. In this **review** , we discuss how the SIV-infected macaque has provided unequivocal evidence for cytotoxic T-lymphocyte (CTL) selection of viral escape variants. This improved understanding of CTL escape may influence human immunodeficiency virus ( **HIV** ) **vaccine** design as well as our understanding of HIV pathogenesis.

**21/3,K/22 (Item 22 from file: 155)**

DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

11522515 PMID: 11708271
**Shooting blanks. "Science" writer Jon Cohen speaks of how the search for an HIV vaccine has strayed. Interview by Bob Roehr.**
Cohen J
IAPAC monthly (United States) Sep 2001, 7 (9) p268-70, Journal Code: 101087241
Document type: Interview; Newspaper Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**Shooting blanks. "Science" writer Jon Cohen speaks of how the search for an HIV vaccine has strayed. Interview by Bob Roehr.**
; AIDS Vaccines--standards--ST; Animals; Disease Models, Animal; Drug

Industry--organization and administration--OG; Haplorhini; Health Policy --trends--TD; Journalism, Medical; Leadership; Needs Assessment; Peer **Review** , Research; United States

**21/3,K/23 (Item 23 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


11507946 PMID: 11672892
**Rational development of prophylactic HIV vaccines based on structural and regulatory proteins.**
Mooij P; Heeney J L
Department of Virology, Biomedical Primate Research Centre, P.O. Box 3306, 2288 Rijswijk, The Netherlands.
Vaccine (England) Nov 12 2001, 20 (3-4) p304-21, ISSN 0264-410X Journal Code: 8406899
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

The severity of the AIDS epidemic clearly emphasises the urgent need to expedite **HIV vaccine** candidates into clinical trials. Prophylactic **HIV vaccine** candidates have been evaluated in non-human primates. Based on specific proof of principle studies the first phase III clinical studies have recently begun in humans. However, a truly effective **HIV vaccine** is not yet at hand and many problems related to specific properties of the virus remain to be overcome. Previously proven empirical approaches have largely failed and now rational thinking based on an understanding of immunity to lentiviral infections is needed. This **review** addresses the scientific problems and complications facing the development of an **HIV vaccine** as well as the possible strategies currently available to overcome these problems. Recent attention has focussed on identifying the immune correlates and mechanisms of protection...

**21/3,K/24 (Item 24 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


11260442 PMID: 11339361
HIV vaccine **development at Duke University Medical Center.**
Haynes B F; Liao H X; Staats H F; Alam M S; Weinhold K J; Montefiori D C
Department of Medicine, The Duke Center for Aids Research, Duke University Medical Center, Durham, NC 27710, USA. hayne002@mc.duke.edu
Immunologic research (United States) 2000, 22 (2-3) p263-9, ISSN 0257-277X Journal Code: 8611087
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

HIV vaccine **development at Duke University Medical Center.**
With the AIDS epidemic continuing to spread throughout the world, development of a safe, practical, and effective **HIV vaccine** is a national priority. **HIV vaccine** research efforts are currently targeted towards design of HIV immunogens that induce both cellular and humoral immunity. This brief **review** summarizes ongoing work at the Duke University School of Medicine on **HIV vaccine** development.

**21/3,K/25 (Item 25 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)

10836864 PMID: 10964278
**Vaccines for the control of HIV/AIDS.**
Gotch F; Rutebemberwa A; Jones G; Imami N; Gilmour J; Kaleebu P; Whitworth J
Department of Immunology, Imperial College of Science and Medicine, London, UK. f.gotch@ic.ac.uk
Tropical medicine & international health - TM & IH (ENGLAND) Jul 2000, 5 (7) pA16-21, ISSN 1360-2276 Journal Code: 9610576
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

This **review** discusses the feasibility of an **HIV vaccine** and describes the history, efficacy and potential to succeed of old and new vaccine concepts.

**21/3,K/26 (Item 26 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


10833466 PMID: 10963285
**Challenges in the development of an effective** HIV vaccine **: current approaches and future directions.**
Klein E; Ho R J
Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, 98195-7610, USA.
Clinical therapeutics (UNITED STATES) Mar 2000, 22 (3) p295-314; discussion 265, ISSN 0149-2918 Journal Code: 7706726
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

**Challenges in the development of an effective** HIV vaccine **: current approaches and future directions.**
OBJECTIVE: The intent of this **review** is to investigate and discuss why developing a successful **HIV vaccine** has been so challenging, first by examining the molecular biology of the virus and how HIV interacts with the immune system, and then reviewing past viral vaccine successes as well as future directions for **HIV vaccine** research. BACKGROUND: Since HIV appeared in the United States in the early 1980s, an estimated 40 million people worldwide have been infected with the virus...

... vaccine entering the market in the foreseeable future. METHODS: MEDLINE was searched for articles written between 1966 and June 1999. Search terms used were AIDS, **HIV vaccine** , HIV-1, HIV-2, vaccines, and human immunodeficiency virus. RESULTS: Only 2 candidates for an **HIV vaccine** are currently in phase III clinical trials (1 in the United States and 1 in Thailand). The efficacy of these vaccines when applied to the...

**21/3,K/27 (Item 27 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


10786278 PMID: 10912619
**Listeria monocytogenes as an alternative vaccine vector for HIV.**
Mata M; Paterson Y
University of Pennsylvania Medical School, Department of Microbiology, Philadelphia, USA.
Archivum immunologiae et therapiae experimentalis (POLAND) 2000, 48 (3) p151-62, ISSN 0004-069X Journal Code: 0114365

Document type: Journal Article; Review; Review, Academic
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

The necessity for an **HIV vaccine** and a brief **review** of current strategies towards this aim are given here to set into context contemporary studies towards exploiting the bacterium Listeria monocytogenes as an **HIV vaccine** vector. The cell biology and immunology of this unusual intracellular organism are also reviewed, in addition to its application to introducing viral antigens, including HIV...

**21/3,K/28 (Item 28 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)


10595587 PMID: 10701170 Record Identifier: 64608
**Ethical considerations in international** HIV vaccine **trials: summary of a consultative process conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS).**
Guenter D; Esparza J; Macklin R
Department of Family Medicine, McMaster University, Hamilton, Canada.
Journal of medical ethics (ENGLAND) Feb 2000, 26 (1) p37-43, ISSN 0306-6800 Journal Code: 7513619
6 fn.; Full author name: Esparza, Jose; Full author name: Guenter, Dale; Full author name: Macklin, Ruth; KIE BoB Subject Heading: AIDS/human experimentation; KIE BoB Subject Heading: human experimentation/foreign countries
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Other Citation Owner: KIE
Record type: Completed

**Ethical considerations in international** HIV vaccine **trials: summary of a consultative process conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS).**
... international consultation; its purpose was further to define the important ethical issues and to formulate guidance that might facilitate the ethical design and conduct of **HIV vaccine** trials in international contexts. This paper summarises the major outcomes of the UNAIDS consultative process.
; AIDS Vaccines; Attitude to Health; Bioethical Issues; Consensus; Control Groups; Ethical **Review** ; Ethics; Ethics, Research; Health Priorities; Moral Obligations; Needs Assessment; Nontherapeutic Human Experimentation; Patient Advocacy; Research Design--standards--ST; Research Subjects; Social Justice; Social Values; Socioeconomic...

**21/3,K/29 (Item 1 from file: 5)**
DIALOG(R)File 5:Biosis Previews(R)


0015069003 BIOSIS NO.: 200400436922
HIV vaccine **and immunotherapy approaches**
AUTHOR: Gruber Andreas (Reprint)
AUTHOR ADDRESS: Neptunusstr 142, NL-2586 GX, Den Haag, Netherlands** Netherlands
AUTHOR E-MAIL ADDRESS: agruber@ucsd.edu
JOURNAL: Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents 4 (1): p21-25 March 2004 2004
MEDIUM: print
ISSN: 1568-0134 _(ISSN print)
DOCUMENT TYPE: Article; Literature Review

RECORD TYPE: Citation
LANGUAGE: English

HIV vaccine **and immunotherapy approaches**
DESCRIPTORS:
MISCELLANEOUS TERMS: ...Literature **Review**

**21/3,K/30 (Item 2 from file: 5)**
DIALOG(R)File 5:Biosis Previews(R)


0015010781 BIOSIS NO.: 200400381570
**The problems of variability of the human immunodeficiency virus**
AUTHOR: Ivans'ka N V; Trokhimchuk T Yu
JOURNAL: Biopolimery i Kletka 20 (3): p171-181 May 2004 2004
MEDIUM: print
ISSN: 0233-7657 _(ISSN print)
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: Ukrainian

ABSTRACT: This **review** deals with variability of the human immunodeficiency virus (HIV) and the epidemiological consequences of such variability. The level of the HIV variability is extremely high...
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: **HIV vaccine** --
?

| Set | Items | Description |
|---|---|---|
| S1 | 0 | (HIV-1 (W) VACCINE) |
| S2 | 2077 | HIV (W) VACCINE |
| S3 | 0 | S2 AND (PRIME-BOOST) |
| S4 | 0 | PRIME-BOOST (W) VACCINE |
| S5 | 148 | (PRIME (W) BOOST) (W) (VACCINE OR IMMUNIZATION) |
| S6 | 6 | S2 AND S5 |
| S7 | 2 | RD (unique items) |
| S8 | 9 | S5 AND (HIV-1) |
| S9 | 9 | RD (unique items) |
| S10 | 7 | S9 NOT S7 |
| S11 | 3 | S5 AND BX08 |
| S12 | 1 | RD (unique items) |
| S13 | 0 | S5 AND AVIOPOXVIRUS |
| S14 | 3 | S5 AND AVIPOXVIRUS |
| S15 | 3 | RD (unique items) |
| S16 | 0 | S5 AND (ATTENUATED (W) VIRAL (W) VECTOR) |
| S17 | 2 | (ATTENUATED (W) VIRAL (W) VECTOR) |
| S18 | 2 | RD (unique items) |
| S19 | 227 | S2 AND REVIEW |
| S20 | 140 | S19 NOT PY<2000 |
| S21 | 97 | RD (unique items) |

?
COST
23nov04 16:31:53 User259876 Session D693.2
$6.45 2.016 DialUnits File155
$8.61 41 Type(s) in Format 3
$8.61 41 Types
$15.06 Estimated cost File155
$9.11 1.626 DialUnits File5
$7.00 4 Type(s) in Format 3
$7.00 4 Types
$16.11 Estimated cost File5
$11.30 1.153 DialUnits File73
$11.30 Estimated cost File73
OneSearch, 3 files, 4.795 DialUnits FileOS

```
      $5.49  INTERNET
     $47.96  Estimated cost this search
     $48.85  Estimated total session cost   5.025 DialUnits
?
```

**Return to logon page!**